OTC Markets EXMKT - Delayed Quote USD
PsyBio Therapeutics Corp. (PSYBF)
At close: November 4 at 3:00 PM EST
Breakdown
TTM
12/31/2022
12/31/2021
Cost of Revenue
50.0000
50.0000
62.5000
Gross Profit
-50.0000
-50.0000
-62.5000
Operating Expense
2,742.7330
4,706.1820
9,605.8660
Operating Income
-2,792.7330
-4,756.1820
-9,668.3660
Net Non Operating Interest Income Expense
-13.2520
-21.0520
--
Other Income Expense
-13.3750
-108.8290
-1,350.5120
Pretax Income
-2,819.3600
-4,886.0630
-11,018.8780
Net Income Common Stockholders
-2,819.7220
-4,886.0630
-11,018.8780
Diluted NI Available to Com Stockholders
-2,819.7220
-4,886.0630
-11,018.8780
Basic EPS
-0.02
-0.04
-0.10
Diluted EPS
-0.02
-0.04
-0.10
Basic Average Shares
119,753.8360
111,810.1600
106,935.2600
Diluted Average Shares
119,753.8360
111,810.1600
106,935.2600
Total Expenses
2,792.7330
4,756.1820
9,668.3660
Net Income from Continuing & Discontinued Operation
-2,819.7220
-4,886.0630
-11,018.8780
Normalized Income
-2,803.8240
-4,749.1220
-9,578.7200
Interest Expense
13.2520
21.0520
--
Net Interest Income
-13.2520
-21.0520
--
EBIT
-2,806.1080
-4,865.0110
-11,018.8780
EBITDA
-2,692.0480
-4,712.9310
-11,018.8780
Reconciled Cost of Revenue
50.0000
50.0000
62.5000
Reconciled Depreciation
114.0600
152.0800
--
Net Income from Continuing Operation Net Minority Interest
-2,819.7220
-4,886.0630
-11,018.8780
Total Unusual Items Excluding Goodwill
-15.8980
-136.9410
-1,440.1580
Total Unusual Items
-15.8980
-136.9410
-1,440.1580
Normalized EBITDA
-2,676.1500
-4,575.9900
-9,578.7200
12/31/2021 - 4/23/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade